Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPP5C | P53041 | 1/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520813 | 1.00 | TDP1 (0.39) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL15672321 | 1.00 | TDP1 (0.39) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL19604953 | 0.87 | KDM4E (0.31) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL13694674 | 0.83 | — | — | |
| SCHEMBL21689115 | 0.83 | — | — | |
| SCHEMBL19067982 | 0.79 | ALDH1A1 (0.36) | — | |
| SCHEMBL597567 | 0.77 | KDM4E (0.31) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL4352284 | 0.74 | KMT2A (0.41) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL1739727 | 0.74 | KMT2A (0.41) | TDP1KDM4EGMNNPPM1BLMNA | |
| SCHEMBL1473414 | 0.74 | KMT2A (0.41) | TDP1KDM4EGMNNPPM1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415496-B2 | Biobased polyesters | Amyris, Inc. | 2013-04-09 | — | — | US | disclosed |
| US-8367859-B2 | Cyclohexane 1,4 carboxylates | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367858-B2 | Terephthalic and trimellitic based acids and carboxylate derivatives thereof | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288263-A1 | BIOBASED POLYESTERS | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110282078-A1 | CYCLOHEXENE 1,4 -CARBOXYLATES | DRATHS CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288310-A1 | CYCLOHEXANE 1,4 CARBOXYLATES | CNR2, CBR1, CCR4 | TDP1 2258/4885KDM4E 116/4885GMNN 1109/4885 |
| US-20110282078-A1 | CYCLOHEXENE 1,4 -CARBOXYLATES | CBR1, MCM4, CCR4 | TDP1 2649/4885KDM4E 102/4885GMNN 905/4885 |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | TRIM4, DDT, PICALM | TDP1 1287/4885KDM4E 739/4885GMNN 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.